- Allogene CEO to step down; Agios drug fails key test<figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…BioPharma Dive · 1mo ago↗ source
- Can a chaotic FDA still deliver on faster drug development?<figure><div><img src="https://imgproxy.divecdn.com/GjzgQSCxYItE_nvCVcgr1dRWi34d0viitteF7G59vHs/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMjAxMjA4MDM3LmpwZ…BioPharma Dive · 1mo ago↗ source
- #ASCO26: Bristol Myers details Phase 3 trial win for Pomalyst successorBristol Myers Squibb’s next-gen multiple myeloma drug cut the risk of disease progression or death for certain patients by 52% when added on top of a combination treatment regimen. The New Jersey…